Peringkat dalam Saham
#15162
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development... Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Harga Saham
$3.70
Terakhir disinkronkan: 2026-08-28
Kapitalisasi Pasar
$369.01M
Perubahan (1 tahun)
35.04%
Perdagangan Hansa Biopharma AB (HNSBF)
Pendapatan untuk Hansa Biopharma AB (HNSBF)
Pendapatan pada Sep 2026 TTM: 0
Menurut laporan keuangan terbaru dari Hansa Biopharma AB, pendapatan saat ini (TTM) adalah 0. Pada tahun 2026, perusahaan menghasilkan pendapatan sebesar 0 sama dengan pendapatan pada tahun 2026 yang sebesar 0. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Hansa Biopharma AB dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun |
Pendapatan |
Mengubah |
|
Tidak cukup data untuk tanggal yang disediakan. |
Pendapatan untuk perusahaan serupa atau pesaing
| Perusahaan |
Pendapatan |
Perbedaan Pendapatan |
Negara |
|
|
$2.54B |
-
|
US
|
|
|
- |
-
|
SE
|
|
|
- |
-
|
FR
|
|
|
- |
-
|
IT
|
|
|
$830.81M |
-
|
US
|
